Drug Interaction Study of Isavuconazole and Warfarin in Healthy Male Subjects

Astellas

Status and phase

Completed

Phase 1

Conditions

Healthy Volunteers

Pharmacokinetics of S- and R-warfarin

Pharmacodynamics of Warfarin

Pharmacokinetics of Isavuconazole

Treatments

Drug: Warfarin

Drug: Isavuconazole

Study type

Interventional

Funder types

Industry

Identifiers

NCT01657825

9766-CL-0033

Details and patient eligibility

About

The purpose of this study is to assess the effect of multiple doses of isavuconazole on the pharmacokinetics (PK) of warfarin after single dose administration.

Full description

Subjects will receive a single dose of warfarin on Day 1 followed by a 15 day wash-out period (time from warfarin dosing to isavuconazole dosing).

On Days 16 and 17, isavuconazole will be dosed three times daily (TID). TID doses will be administered 8 hours apart. On Days 18 through 28, isavuconazole will be administered once daily (QD). All subjects will be administered a single dose of warfarin on Day 20. A follow up visit will occur approximately 7 days after the last dose of isavuconazole. Blood samples for pharmacokinetics will be collected throughout the study.

Enrollment

20 patients

Sex

Male

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Subjects must have BMI of 18 to 32 kg/m2 and a body weight of at least 45 kg
Subjects must have normal laboratory values especially for ALT, AST, protein C and S, and prothrombin time

Exclusion criteria

The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmia or torsade de pointes, structural heart disease, or family history of Long QT syndrome (suggested by sudden death of a close relative at a young age due to possible or probable cardiac causes)
The subject has a positive result for hepatitis C antibodies or hepatitis B surface antigen at Screening or is known to be positive for human immunodeficiency virus (HIV)
The subject has a known or suspected allergy to any of the components of the trial products or the azole class of compounds, or a history of multiple and/or severe allergies to drugs or foods (as judged by the investigator), or a history of severe anaphylactic reactions
The subject is a smoker (any use of tobacco or nicotine containing products) within 6 months prior to Screening
The subject has had treatment with prescription drugs or complementary and alternative medicines within 14 days prior to Day -1, or over-the-counter medications within 1 week prior to Day -1
The subject has received an experimental agent within 30 days or 5 half-lives, whichever is longer prior to Day -1
The subject has a recent history (within the last 2 years) of drug or alcohol abuse, as defined by the investigator, or a positive drug and/or alcohol screen